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Defects in DNA repair give rise to genomic instability, leading to
neoplasia. Cancer cells defective in one DNA repair pathway can
become reliant on remaining repair pathways for survival and pro-
liferation. This attribute of cancer cells can be exploited therapeu-
tically, by inhibiting the remaining repair pathway, a process
termed synthetic lethality. This process underlies the mechanism
of the Poly-ADP ribose polymerase-1 (PARP1) inhibitors in clinical
use, which target BRCA1 deficient cancers, which is indispensable
for homologous recombination (HR) DNA repair. HR is the major
repair pathway for stressed replication forks, but when BRCA1 is
deficient, stressed forks are repaired by back-up pathways such as
alternative nonhomologous end-joining (aNHEJ). Unlike HR, aNHEJ
is nonconservative, and can mediate chromosomal translocations.
In this study we have found that miR223-3p decreases expression
of PARP1, CtIP, and Pso4, each of which are aNHEJ components. In
most cells, high levels of microRNA (miR) 223–3p repress aNHEJ,
decreasing the risk of chromosomal translocations. Deletion of the
miR223 locus in mice increases PARP1 levels in hematopoietic cells
and enhances their risk of unprovoked chromosomal transloca-
tions. We also discovered that cancer cells deficient in BRCA1 or
its obligate partner BRCA1-Associated Protein-1 (BAP1) routinely
repress miR223-3p to permit repair of stressed replication forks via
aNHEJ. Reconstituting the expression of miR223-3p in BRCA1- and
BAP1-deficient cancer cells results in reduced repair of stressed
replication forks and synthetic lethality. Thus, miR223-3p is a neg-
ative regulator of the aNHEJ DNA repair and represents a thera-
peutic pathway for BRCA1- or BAP1-deficient cancers.
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DNA replication is not a smooth and continuous process, butrather prone to interruptions (1, 2). DNA damage or nucle-
otide depletion can induce stalling of the replication machinery (3,
4), which can result in replication stress and subsequent fork
collapse, with disassociation of the replication apparatus (5, 6). As
such, replication stress is a common etiology of genomic in-
stability, resulting in either cell death or neoplastic transformation
(4, 6–8). HR is the most common pathway for stressed replication
fork repair and restart (5, 7, 8). The rate-limiting step in HR is the
nucleolytic resection of the 5′ strand at a DNA free end, initiated
when BRCA1/CtIP replaces 53BP1/RIF1/Shieldin at the site of
DNA damage (9–12). After 5′ strand resection (13–16), BRCA2
then loads the RAD51 recombinase onto the 3′ single-stranded
DNA for invasion of the sister chromatid (17–19), which results in
Holliday junction formation that is later resolved by MUS81 and
SLX4 (20, 21). Germline or acquired mutations in BRCA1 or its
interacting partner BAP1 result in defects in the HR pathway, and
subsequent replication fork instability and oncogenesis (22–25).
HR-deficient cancers become addicted to other repair pathways to
resolve replication fork stress such as aNHEJ (26–30). This ad-
diction is a singular weakness of these cancer cells, and can be
targeted with therapeutic agents (8, 25, 29, 30), generating syn-
thetic lethality. This synthetic lethality underlies the efficacy of
PARP1 inhibitors in breast, ovarian, and prostate cancers that
harbor inherited or acquired mutations in BRCA1 (31, 32).
PARP1 can initiate aNHEJ by displacing the Ku complex from
the DNA double-strand break (33, 34). CtIP, Pso4, and Mre11
then mediate limited 5′ end resection, followed by DNA poly-
merase theta promoting microhomology annealing (27–29).
DNA ligase 1 or 3 with XRCC1 then promote ligation of the free
DNA ends (27, 33). Pharmacologic inhibitors of PARP1 lock it
onto DNA, generating obstacles that stall replication forks,
which in BRCA1- or BAP1-mutant cells cannot be repaired by
HR (31, 32, 35). PARP1 inhibition also prevents the use of the
aNHEJ back-up repair pathway to resolve the replication forks
stalled by PARP1 locked on DNA, resulting in fork collapse and
cell death (8, 25, 27). While aNHEJ promotes repair of stressed
replication forks in BRCA1/BAP1-defective cells, it comes at a
cost; aNHEJ can mediate chromosomal translocations (33, 34).
This occurs when aNHEJ erroneously anneals and then ligates
free DNA ends on distinct chromosomes (26, 33, 34). The three
FDA-approved PARP1 inhibitors, olaparib, rucaparib, and nir-
aparib, have each shown impressive response rates in HR-
deficient cancers (36–41). However, these agents can occasionally
lead to myelodysplastic syndrome, and resistance can develop
(30, 41, 42). In this study, we found that the microRNA species
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miR223-3p is a negative regulator of aNHEJ, likely to restrain
aNHEJ from generating aberrant chromosomal translocations
that would lead to genomic instability. Importantly, we discov-
ered that cancer cells deficient in HR repress miR223-3p strand
selection and instead express miR223-5p. Reconstituting ex-
pression of miR223-3p is synthetically lethal to BRCA1- and
BAP1-defective cancer cells, demonstrating its potential as an
effective cancer therapeutic agent.
Results
MiR223-3p Down-Regulates aNHEJ Components. MiR223-3p has a
strong seed sequence match for the 3′ UTR of PARP1, the 3′
UTR of CtIP, and exon 1 of Pso4, each of which is important for
aNHEJ (33, 34) (Fig. 1A). Consistent with this, transfection of
miR223-3p in multiple cell types markedly decreased PARP1,
CtIP, and Pso4 protein levels by an average of fivefold, 2.5-fold,
and twofold, respectively (P value < 0.001, <0.05, >0.05, re-
spectively), but did not affect the levels of other aNHEJ com-
ponents such as Ligase III, Pol Q, and XRCC1 (Figs. 1 B and C
and SI Appendix, Fig. S1 C and D). However, we observed that
the expression levels of PARP1 mRNA were not affected by
miR223-3p (SI Appendix, Fig. S1A), suggesting that miR223-3p is
a translational repressor. To confirm that miR223-3p mediates
translational repression, we performed luciferase assays where
the reporter was fused to PARP1 3′UTR. When the reporter
construct is cotransfected with the miR223-3p, we found a 20-
fold decrease in the luciferase activity in cells transfected with
the miR223-3p compared with control cells transfected with a
scrambled microRNA (Fig. 1D, P value < 0.01). We did not
observe cleaved PARP1 indicative of apoptosis activation upon
transfection of miR223-3p in any cell line (SI Appendix, Fig.
S1B). We measured aNHEJ after transfection with miR223-3p
using two reporter systems, EJ2-GFP (43) and MMEJ-GFP (8).
We found that when both of these reporter systems were trans-
fected with miR223-3p, aNHEJ repair efficiency was reduced 10-
fold (Fig. 1 E and F, P value < 0.001).
MiR223-3p Represses Chromosomal Translocation in Hematopoietic
Cells. MiR223-3p is highly expressed in hematopoietic cells and
is involved in the regulation of granulopoiesis (44). However, the
functional relationship between miR223-3p and the maintenance
of genomic stability in the hematopoietic system has not been
defined. We first studied the change in miR223-3p expression
levels in hematopoietic cell lines in response to replication stress.
HL-60 cells (HR proficient) treated with 50 μM Ara-C rapidly
decreased the expression of endogenous miR223-3p by 10-fold at
1 h after treatment as measured by qRT-PCR (Fig. 2A). This
decrease in miR223-3p upon replication stress is accompanied by
an increase in PARP1 protein levels by twofold (Fig. 2 B and C).
MiR223-3p levels returned to baseline when the cells were
released from Ara-C (Fig. 2D). It is certainly possible that
there were transcriptional regulatory changes in PARP1 from
Ara-C, and PARP1 changes were from that and not miR223-3p
reduction.
We next investigated the occurrence of chromosomal translo-
cations following miR223-3p-mediated down-regulation of aNHEJ.
We treated Jurkat cells (HR proficient) with VP16, known to in-
duce chromosomal translocations (34), and then scored metaphases
for the translocation phenotypes, dicentric, ring, cruciform, and
double minute chromosomes. We found that transfecting miR223-
3p decreased PARP1 protein levels and decreased chromosomal
translocation events compared with the control group (Fig. 2 E and
F), consistent with the known role of PARP1 in aNHEJ-mediated
chromosomal translocations (3, 34).
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Fig. 1. MiR223-3p down-regulates aNHEJ compo-
nents PARP1, CtIP, and Pso4 in mammalian cells. (A)
Pairing of miR223-3p to the 3′UTR region of PARP1
mRNA and CtIP mRNA, and to exon 1 of PSO4. (B)
Western blot showing the levels of PARP1, CtIP, and
Pso4 upon miR223-3p transfection in MDA-MB-436
cells. (C) Densitometry of Western blots showing
levels of aNHEJ components (n = 3). (D) Luciferase
reporter of PARP1 3′ UTR upon miR223-3p mimic
transfection. (E and F) Measurement of aNHEJ in the
EJ2-GFP (E) and MMEJ-GFP (F) cell reporter systems
after transfection of miR223-3p. GFP-expressing cells
indicate productive aNHEJ repair. (*-P < 0.05, **-P <
0.01, ***-P < 0.001, ****-P < 0.0001 for all figures).
41
2
3
FE
BA
D
C
PARP1
β-actin
Fig. 2. MiR22-3p represses chromosomal translocation in hematopoietic
cells. (A) QRT-PCR showing the endogenous levels of miR223-3p at different
time points after Ara-C treatment in HL-60 cells. (B) Western analysis
showing the PARP1 protein levels at different time points after Ara-C
treatment in HL60 cells. (C) Quantitation of the Western blots showing
relative levels of PARP1 in HL-60 cells after Ara-C treatment. (D) QRT-PCR
showing levels of endogenous miR223-3p in HL-60 cells at different time
points after release from Ara-C treatment. (E) Representative confocal
metaphase images showing chromosomal translocation phenotypes in
Jurkat cells after VP16 exposure (1- Double minutes, 2- Cruciform structure,
3- Dicentric chromosomes, and 4- Ring chromosome). (F) Percentage of cells
showing different chromosomal translocation phenotypes in Jurkat cells
treated with VP16 with or without prior transfection of miR223-3p.
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MiR223-Deleted Mice Exhibit Increased Chromosomal Aberrations.
Loss of miR223 has been reported in AML patients (44), which
could be one origin of leukemogenic translocations. We hypoth-
esized that the genetic loss of miR223 would result in increased
chromosomal translocations due to increased aNHEJ in hemato-
poietic cells. Immunohistology of bone marrow from mice with
homozygous deletion of the miR223 locus demonstrated that
there was an increased fraction of hematopoietic cells expressing
PARP1 protein compared with wild-type (WT) controls (Fig. 3 A
and B. P value < 0.05) (43). Further, miR223−/− hematopoietic
cells had a twofold increase in unprovoked hematopoietic cell
chromosomal translocations compared with the WT (Fig. 3 C and
D. P value < 0.05), consistent with a role for miR223-3p in
maintaining genomic stability.
MiR223-3p Induces Synthetic Lethality in HR-Deficient Cancers.Given
that miR223-3p decreased aNHEJ efficiency, we hypothesized
that HR-deficient cancers would not tolerate its expression.
BRCA1 is in a complex with BAP1, and both are required for
HR (24, 45, 46). We found that all BRCA1- and BAP1-deficient
cancer cells tested in this study suppressed expression of
miR223-3p and instead processed the 5p form of miR223 to
maturity (Fig. 4A and SI Appendix, Fig. S2A), opposite of all HR-
proficient cell lines examined (Fig. 4A and SI Appendix, Fig.
S2B). Continued expression of miR223-3p in HR-deficient can-
cers would repress aNHEJ, which would decrease those cells’
ability to repair replication stress (25–29). Significantly, when we
repressed BRCA1 in the HR-proficient breast cancer cell line
MCF7, miR223-3p levels declined as well (SI Appendix, Fig.
S2D). We next studied whether reconstitution of miR223-3p in
BRCA1- or BAP1-deficient cancer cells could induce synthetic
lethality. We found that a single transfection of miR223-3p was
highly cytotoxic to BRCA1-deficient breast and ovarian cancer
cells, and to BAP1-mutant malignant pleural mesothelioma
(MPM) cells (Fig. 4 B and C and SI Appendix, Fig. S2C). Specifi-
cally, a single transfection of 25 nMmiR223-3p resulted in fourfold
decrease in clonogenicity in BRCA1-mutant MDA-MB-436 breast
cancer cells (Fig. 4C. P value < 0.0001), 40-fold decrease in
BRCA1-mutant UWB1.289 ovarian cancer cells (Fig, 4C. P value <
0.0001) and 20-fold decrease in H2452 BAP1-mutant mesothelioma
cells (SI Appendix, Fig. S2C, P value < 0.001). Injecting BRCA1-
mutant MDA-MB-436 luciferase cells transfected with miR223-3p
into NSG mice showed significantly decreased tumor growth
compared with the mice with miR-control transfected cells (SI
Appendix, Fig. S3C). Reconstituting miR223-3p in MDA-MB-436
increased the fraction of cells in S-phase (SI Appendix, Fig. S4B).
However, transfecting miR223-3p into the HR-proficient MCF7
breast cancer cells did not appreciably alter their clonal cell sur-
vival (Fig. 4C). Depleting BRCA1 in MCF7 cells followed by
miR223-3p transfection resulted in significant decrease in the
clonal survival (SI Appendix, Fig. S3B). BRCA1-mutant HCC1937
cells are resistant to relatively high concentrations of olaparib (42)
(Fig. 4E). However, a single transfection of 25 nM miR223-3p
resulted in a fourfold decrease in clonogenicity in the HCC1937
cells (Fig. 4F, P value < 0.001).
Reconstituting miR223-3p Blocks Stressed Replication Fork Repair in
BRCA1- or BAP1-Deficient Cancer Cells. We next measured the
fraction of active replication forks in BRCA1- or BAP1-deficient
cancer cells after transfection with miR223-3p. First, we assessed
BrdU incorporation in BRCA1-deficient breast cancer MDA-
MB-436 cells (Fig. 5 A and B) and in BAP1-mutant MPM cells
(H2452) (SI Appendix, Fig. S4A). We found that the MDA-MB-
436 cells transfected once with miR223-3p had a threefold de-
crease in BrdU foci compared with controls (Fig. 5 A and B,
P value < 0.0001), while the H2452 cells exhibited a fourfold de-
crease (SI Appendix, Fig. S4A, P value < 0.001). The decrease in
BrdU foci reflects perturbation of DNA replication, suggesting
that miR223-3p interferes with replication forks by decreasing
the capability of aNHEJ to manage replication stress in BRCA1-
and BAP1-deficient cells (42, 43, 47). We used DNA fiber
analysis to assess repair and restart of stressed replication forks
in the above BRCA1- and BAP1-deficient cancer cells after
transfection of miR223-3p (Fig. 5C) (9, 14). Replication was
stressed by deoxynucleotide depletion with hydroxyurea (HU)
(1–4). The percentage of stalled forks were significantly higher in
the BRCA1-deficient MDA-MB-436 cells and BAP1-deficient
H2452 cells transfected with miR223-3p (Fig. 5D and SI Ap-
pendix, Fig. S4C). After release from replication stress, re-
constitution of miR223-3p resulted in a twofold decrease in the
initial repair and restart of stalled replication forks in MDA-MB-
436 cells (Fig. 5E, P value < 0.001) and a twofold decrease in the
H2452 cells (SI Appendix, Fig. S4C, P value < 0.001). MiR223-3p
reconstitution also decreased the fraction of new forks starting
after release from stress that stem from firing from normally
dormant origins by fivefold in MDA-MB-436 cells (Fig. 5F,
P value < 0.001) and by fourfold in H2452 cells (SI Appendix, Fig.
S4C, P value < 0.001). However, the MDA-MB-436 cells ex-
posed to miR223-3p ultimately recovered their ability to restart
stalled replication forks to the same extent as controls. There
were fewer new forks in the miR223-3p-reconstituted MDA-MB-
436 cells than controls at all time points, implying a role for
aNHEJ components in the firing of new replication origins (Fig.
5F). Nearly identical findings were seen in the BAP1-mutant
H2452 mesothelioma cells after reconstitution of miR223-3p
(SI Appendix, Fig. S4C), indicating that BAP1-deficient cancers
also require aNHEJ for stressed replication fork repair, and thus
are sensitive to miR223-3p restoration.
MiR223-3p Reconstitution Induces Genomic Instability in BRCA1- and
BAP1-Deficient Cells. We tested whether miR223-3p-induced
BRCA1- or BAP1-deficient cell delay of stressed replication
fork repair and restart led to genomic instability. Unrepaired
stressed replication forks can result in unresolved fork cleavage
and ultimately nucleolytic destruction of fork structures (47, 48).
Cleaved and/or degraded replication forks can be identified by
the presence of γH2Ax (9, 49). Therefore, we measured the
number of γH2Ax foci using immunofluorescence microscopy in
BA
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Fig. 3. MiR223 KO mice exhibit increased unprovoked chromosomal aber-
rations. (A) Representative images for PARP1 protein assessed by immuno-
histology in the bone marrow of miR223 wild-type (WT) and genetically
deleted mice. (B) Percentage of PARP1-expressing cells in the bone marrow
of miR223−/− and WT mice. (C) Representative confocal images showing
metaphase chromosomes in the MiR223−/− and WT mouse bone marrow.
Cruciform structures indicative of chromosomal fusions are shownwith arrows.
(D) Percentage of chromosomal aberrations per metaphase in MiR223−/− and
WT mice.
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the BRCA1-mutant MDA-MB-436 and BAP1-mutant H2452
cells. We found that the miR223-3p-reconstitued in these cancer
cells had a twofold increase in the accumulation of γH2Ax foci
(Fig. 6 A and B, P value < 0.05, SI Appendix, Fig. S5A). We also
found increased phosphorylation of ATR, RPA and Chk1 by
Western blot, again consistent with the accumulation of stressed
replication forks (Fig. 6 C and D). These data indicate that
restoration of miR223-3p in BRCA1- and BAP1-deficient cancer
cells results in replication fork structural damage. Genomic in-
stability arising from unrepaired stressed replication forks can
also be measured by abnormal nuclear structures such as
micronuclei and bridging. These nuclear aberrancies are the
result of mitotic catastrophe, which occurs when aberrantly re-
solved damaged fork structures result in fused chromosomes via
classical NHEJ (9, 50). Acentric chromosomes are retained in
the parent cell after mitosis, and are seen as micronuclei. Di-
centric chromosomes form a nuclear bridge between daughter
cells (50, 51). We measured these nuclear abnormalities in
BRCA1-deficient MDA-MB-436 breast cancer cells and in
BAP1-deficient H2452 mesothelioma cells. In the MDA-MB-436
cells, there was a twofold increase in nuclear bridging (Fig. 6 E
and F, P value < 0.05) and a fourfold increase in micronuclei
upon miR223-3p transfection in MDA-MB-436 cells (Fig. 6 E
and F, P value < 0.05). In the H2452 cells, there was an eightfold
increase in nuclear bridging (P value < 0.01) and a twofold in-
crease in micronuclei (P value < 0.001) upon miR223-3p trans-
fection (SI Appendix, Fig. S5B).
Discussion
Faithful repair of damaged replication forks is critical for
maintaining genomic stability and suppressing oncogenesis (4, 6).
The proper choice of which DNA repair pathway to use to repair
and restart damaged replication forks is crucial to conserve se-
quence integrity (27, 52). HR repair and restart of damaged
replication forks is conservative, while aNHEJ repair has risk of
aberrant ligation of free DNA ends at such forks, resulting in
chromosomal translocations (33, 34). Such chromosomal ab-
normalities lead to mitotic catastrophe and cell death, or neo-
plastic transformation and cancer (51, 53). Thus, it is not
surprising that cells negatively regulate aNHEJ to promote the
choice of HR to repair stressed replication forks. In this study,
we identified miR223-3p as a repressor of aNHEJ pathway re-
pair efficiency by down-regulating expression of aNHEJ com-
ponents. MiR223-3p is highly expressed in most normal tissues,
especially in hematopoietic cells which have a high proliferative
rate, and thus face a higher risk of replication stress (44). This
Fig. 4. Reconstitution of miR223-3p induces syn-
thetic lethality in HR-deficient cancers. (A) QRT-PCR
comparing the levels of miR223-3p and miR223-5p in
Jurkat cells (HR-replete), MDA-MB-436 (BRCA1-mu-
tant breast cancer cell line), and UWB1.289 (BRCA1-
mutant ovarian cancer cell line). (B) QRT-PCR showing
the expression of miR223-3p following transfection
with miR223-3p in MDA-MB-436 breast cancer cells.
(C) Clonogenic survival assay showing the number
of colonies in MDA-MB-435, UWB1.289, and MCF7
(HR-replete breast cancer) cells upon transfection of
miR223-3p. (D) Clonogenic survival assay in MDA-MB-
436 after depletion of PARP1, CtIP, and PSO4. (E)
Comparison of number of colonies in MDA-MB-436,
and HCC-1937 (BRCA1-mutant breast cancer) cells in
the presence of olaparib. (F) Clonogenic survival assay
in HCC1937 cells after miR223-3p transfection.
Fig. 5. Reconstitution of miR223-3p in HR-deficient
MDA-MB-436 breast cancer cells results in delayed
repair and restart of stressed replication forks. (A)
Representative confocal immunofluorescence mi-
croscopic images of BrdU from scrambled control
and miR223-3p-reconstituted MDA-MB-436 cells ex-
posed to BrdU for 30 min. (B) Fraction of BrdU-positive
cells in control and miR223-3p reconstituted MDA-MB-
436 cells. (C) Experimental protocol and representative
images of DNA fiber assays from control and miR223-
3p-transfected MDA-MB-436 cells pulse-labeled with
IdU for 20 min (red), treated with HU for 120 min, and
then pulse-labeled with CldU (green) for 30 and 60
min. Analysis of stalled replication forks (D), restarted
forks (E), and initiation of new replication forks (F) by
DNA fiber analysis.
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heightened risk of replication stress can lead to genomic in-
stability if such stress is not properly managed by efficient and
conservative fork repair pathways such as HR.
We have previously demonstrated reduced aNHEJ and de-
creased chromosomal translocation when PARP1 is inhibited
(34). We demonstrate here that miR223-3p functions to maintain
genomic stability by decreasing use of aNHEJ. However, when
there is extensive replication stress requiring full deployment of all
relevant repair pathways, levels of miR223-3p decrease. This in-
creases PARP1 levels and promotes aNHEJ activity to address the
repair of damaged replication forks. In miR223−/− mice, hema-
topoietic cells accumulate unprovoked chromosomal transloca-
tions, indicating that miR223-3p maintains steady state genomic
stability in vivo. Conversely, provoked chromosomal translocations
are decreased after over-expression of miR223-3p in cell lines.
Interestingly, miR223-3p−/− mice develop dysplastic hematopoie-
sis (44), similar to myelodysplasia in humans, which could be the
result of genomic instability from unregulated use of aNHEJ in
stressed replication fork repair (33, 34).
Interestingly, BRCA1- and BAP1-deficient cancer cells have
greatly decreased expression of the miR223-3p strand, and in-
stead process premiR223 to miR223-5p (54, 55). Since miR223-
3p inhibits aNHEJ, and aNHEJ replaces HR in processing
stressed replication forks in BRCA1-deficient cancers, it is un-
likely that such cancers could originate in the first place without
repressing miR223-3p. A single transfection of miR223-3p in-
duced synthetic lethality in BRCA1- and BAP1-deficient malig-
nancies, likely by triggering the destruction of required aNHEJ
components CtIP and Pso4 (Fig. 4). SiRNA reduction of PARP1
levels did not result in BRCA1-deficient cell cytotoxicity (Fig.
4D), consistent with the finding that PARP1 inhibitors trap
PARP1 on DNA, and one mechanism of cancer resistance to
such inhibitors is reducing PARP1 levels (35). Reconstituting
miR223-3p in BRCA1- and BAP1-resistant cells led to slowed
repair of stressed replication forks, but ultimately the stressed
forks recovered and restarted. However, we and others have
shown that even a short delay in stressed replication fork repair
results in cell death (3, 9). In cells lacking both HR and aNHEJ,
cleaved replication forks can be fused via 53BP1-dependent
classical NHEJ to give rise to the micronuclei and chromo-
somal bridges as seen here in the BRCA1- and BAP1-deficient
miR223-3p-reconstituted cells (50, 56).
Because BRCA1- and BAP1-deficient malignancies are addicted
to aNHEJ to cope with replication stress, miR223-3p holds pro-
mise as a therapeutic agent for such cancers. Indeed, recon-
stituting miR223-3p led to synthetic lethality even in BRCA1-
mutant cells that were resistant to the PARP1 inhibitor olaparib
(Fig. 4). Thus, MiR223-3p could be an important therapy in
BRCA1- or BAP1-deficient cancers, especially those that develop
resistance to PARP1 inhibitors (57, 58). In addition, since
miR223-3p is normally expressed in most tissues, it would be
well tolerated by normal cells compared with the clinical PARP1
inhibitors, which have some gastrointestinal and hematologic
toxicities (35–40). Notably, BAP1 mutations occur in difficult to
treat malignancies, such as MPM, renal cell carcinoma, uveal
melanoma, and cholangiocarcinoma (24, 45, 46). In summary,
miR223-3p negatively regulates aNHEJ, and is repressed in
BRCA1- and BAP1-deficient cancers. Its reconstitution is syn-
thetically lethal to these cancers, and it would therefore be an
anti-neoplastic therapeutic agent.
Methods and Materials
Cell Culture. Cells and the EJ2-GFP and MMEJ-GFP aNHEJ reporter cells were
cultured as described (8, 9, 41). For inducing DNA damage, cells were treated
with VP16 from Sigma Aldrich (Cat # E1383-25MG) and Cytosine B-D-arabi-
nofuranoside (Ara-C) from Sigma Aldrich (Cat # C6645).
Animal Care.MiR223 knock-out (KO) mice (Cat # 013198), wild-type (WT) mice
(Cat # 002014), and NSG mice (Stock # 005557) were purchased from the
Jackson Laboratory. Housing of the animals and all experimental procedures
were approved by the Institutional Animal Care and Research Advisory
Committee of the University of Florida, Gainesville and University of Texas
Health Science Center at San Antonio.
Antibodies. These are defined in the SI Appendix in the supplemental
materials section.
MiRNA and SiRNA.MirVana miR223-3p microRNA mimic was purchased from
Ambion Life Technologies (Cat # 4464067). Small interfering RNA (siRNA)
against BRCA1 (Cat # L-003461-00-0020), PARP1 (Cat # L-006656-03-0005),
PSO4 (Cat # L-004668-00-0005), and CtIP (Cat # M-011376-00-0005) were
purchased from Dharmacon. All were transfected using Lipofectamine
RNAiMAX from Life Technologies (Cat # 13778–150) at 25 nM.
Luciferase Assay for Assessing PARP1 3′ UTR mRNA Stability. PARP1 3′ UTR
plasmid was transfected using Lipofectamine, and cells were collected and
assessed for luciferase activity using Luc-Pair Dual Luciferase assay kit from
GeneCopoeia (Cat # LPFR-P010). Firefly luciferase activity is normalized
against Renilla luciferase.
Survival Assays. Clonogenic survival assays were performed as described (9, 49).
Cytogenetics. Structural aberrations in Giemsa-stained metaphase chromo-
somes were scored as described (25, 34).
Immunohistology of Mouse Marrow. Femurs from WT and KO mice were
dissected and fixed in 10% neutral buffered formalin for at least 4 d. The
samples were then processed for H&E and immunohistochemical staining
with PARP1 antibody (Santa Cruz Biotechnology, cat# sc-8007).
Micronuclei
A
D E F
B C
Fig. 6. MiR223-3p induces mitotic catastrophe in
HR-deficient MDA-MB-436 breast cancer cells. (A)
Representative confocal immunofluorescence micro-
scopic images of γH2Ax foci after reconstitution of
miR223-3p. (B) Analysis of percentage of cells >5
γ-H2Ax foci in control and miR223-3p-reconstituted
cells. (C) Western analysis and (D) Relative densito-
metric measurements (n = 3) showing the levels of
various DNA damage response proteins such as
phosphorylated ATR, phosphorylated CHK1, and
phosphorylated RPA in control and miR223-3p
reconstituted MDA-MB-436 cells. (E) Representative
DAPI-stained confocal microscopic images showing
abnormal nuclear structures such as micronuclei
(Left) and bridging (Right) in MDA-MB-436 cells with
reconstitution of miR223-3p. (F) Analysis of per-
centage of cells with micronuclei and bridging.
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Nuclear Structure Assays and DNA Damage Foci. Confocal analysis of DAPI-stained
nuclear structural abnormalities such as micronuclei and nuclear bridging were
assessed as described (9). Confocal immunofluorescence γH2Ax foci assays were
performed as described (9).
Replication Fork Analysis. Active replication forks were measured using im-
munofluorescent detection of BrdU foci after DNA denaturation as described
(9). DNA fiber analysis was performed to measure replication fork arrest and
restart in cells transfected with either scramble control or 25 nM miR223-3p
mimic as described (9, 49).
Quantitative Real-Time PCR. CDNA conversion was performed using the first-
strand cDNA synthesis kit for MiRNA from Origene (Cat # HP100042). QRT-
PCR for miR223 was performed on a 7900HT Fast Real37-Time PCR system (ABI)
according to Origene protocol, and ΔCT values were calculated. The primers used
had the following sequences: MiR223-3p - forward (5′TGTCAGTTTGTCAAATACC)
and reverse (5′GAACATGTCTGCGTATCTC), MiR223-5p - forward (5′CGTGTATTT-
GACAAGCTG) and reverse (5′GAACATGTCTGCGTATCTC). U6 RNA was used as an
endogenous control.
Murine s.c. Xenograft Detection. One million BRCA1-deficient MDA-MB-436-
luciferase breast cancer cells were transfected with either miR-Control or
miR223-3p mimic at a concentration of 100 nM and then injected s.c. into the
flank of mice (n = 6/group). Bioluminescent tumor signals were obtained by a
Xenogen IVIS Spectrum imaging system (Perkin-Elmer) once every week af-
ter isoflurane anesthesia as per IACUC protocol.
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